Coronavirus

Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature. Read More

The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19. Read More

Vanderbilt University Medical Center (VUMC) has been named Data Coordinating Center (DCC) for a nationwide platform of studies aimed at “repurposing” existing drugs to treat mild to moderate symptoms of COVID-19. Read More

A switch to paper forms during the COVID-19 pandemic might have hobbled research, but using software with a novel user interface made it possible to accurately extract information from scanned forms. Read More

A more comprehensive, equitable approach to researching gun violence can lead to better policy solutions. Read More

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus. Read More

Researchers at Vanderbilt University Medical Center and the University of Texas Medical Branch (UTMB) at Galveston have discovered what may be the Achilles’ heel of the coronavirus, a finding that may help close the door on COVID-19 and possibly head off future pandemics. Read More

As Vanderbilt prepares to welcome students back to campus for the spring semester, the university is sharing some updates and reminders with staff about plans to bolster community safety during the ongoing COVID-19 pandemic. Read More

As Vanderbilt prepares to welcome more members of its community back to campus for the spring semester, the university is sharing some updates and reminders with postdoctoral scholars about plans to support the Vanderbilt community during the ongoing COVID-19 pandemic. Read More

Vanderbilt looks forward to welcoming undergraduate students back to campus. The university is working hard to prepare and help undergrads have as healthy and safe a semester as possible. Read More

Vanderbilt is sharing updates and reminders with graduate and professional students about its spring semester plans to support the university community during the ongoing COVID-19 pandemic.    Read More

Guided by the lessons learned this fall, Vanderbilt is updating its spring semester testing program and adjusting quarantine guidelines based on new CDC guidance. Read More

Guided by the lessons learned this fall, Vanderbilt is updating its spring semester testing program and adjusting quarantine guidelines based on new CDC guidance. Read More

Guided by the lessons learned this fall, Vanderbilt is updating its spring semester testing program and adjusting quarantine guidelines based on new CDC guidance. Read More

COVID-19 has been linked to cases of new-onset diabetes, diabetes-related emergencies and a higher death rate among diabetes patients. Read More

James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award. Read More

Researchers at Vanderbilt University Medical Center (VUMC) and their colleagues have determined a key factor as to why COVID-19 appears to infect and sicken adults and older people preferentially while seeming to spare younger children.  Read More

Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19. Read More

Findings from a national study published Nov. 9 in the Journal of the American Medical Association (JAMA) “do not support” the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19, the report concludes. Read More

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. Read More